Asia-Pacific remains one of the world's most attractive destinations for life sciences investment.
Growth in pharmaceutical manufacturing, biotechnology research, advanced therapeutics, vaccine production and medical technology continues to drive capital deployment across established hubs, while government priorities around healthcare resilience, sovereign manufacturing and supply chain diversification are creating long-term opportunities.
Singapore is strengthening its position as a biomedical and next-generation therapeutics hub, while Japan, South Korea, India and Australia continue to invest in pharmaceutical innovation and manufacturing capability. China's growing therapeutic development ecosystem is also driving sustained demand for laboratories, manufacturing facilities and specialist production environments.
However, the industry's greatest challenge is not demand but delivery. Power and utility constraints, geopolitical uncertainty, supply chain disruption and persistent labour shortages are placing programme certainty and project viability under growing pressure. Linesight's June 2026 Construction Market Insights report finds that delivery risk across APAC and the GCC is increasingly being driven by execution constraints rather than demand.
Our latest reports highlight how power and utility constraints as a growing challenge across APAC. As demand for digital infrastructure, advanced manufacturing and energy projects continues to grow, competition for reliable utility infrastructure is intensifying.
This issue is especially relevant for pharmaceutical and biotechnology facilities. Manufacturing operations depend on highly reliable power systems, sophisticated HVAC infrastructure, purified water systems, clean steam generation and tightly controlled environmental conditions. Industry guidance on pharmaceutical facility development consistently identifies utilities as critical systems requiring early planning and validation.
These constraints are increasingly influencing project viability. Developers are finding that utility assessments must occur much earlier in the project lifecycle. Delays in securing power connections, substations or water infrastructure can impact programme timelines, increase costs and, in some cases, alter site selection decisions altogether.
As a result, investors are increasingly assessing utility resilience during site selection and due diligence processes. Locations with robust long-term power and water capacity may offer greater delivery certainty and reduced operational risk.
Global disruption is amplifying delivery risks across APAC and the GCC, while supply chain considerations are becoming an earlier and more strategic component of project planning. Cost volatility, longer procurement timelines and logistics uncertainty are all affecting project outcomes.
Life sciences facilities are particularly exposed because of their reliance on specialist materials and equipment. Stainless steel remains one of the most critical commodities due to its widespread use in clean manufacturing environments, process piping and regulated production systems. Demand for copper, electrical infrastructure, air handling systems and specialist cleanroom components also remains high.
Recent disruption affecting shipping routes through the Middle East, including strategic trade corridors linked to the Strait of Hormuz, has demonstrated how quickly global supply chains can be affected. For projects dependent on internationally sourced materials and equipment, any disruption to shipping flows can create additional cost pressure and programme risk.
Perhaps the most significant shift across life sciences construction is the growing importance of long-lead equipment. According to Linesight's June 2026 findings, long-lead equipment now accounts for approximately 35% to 40% of total capital expenditure on many mission-critical and advanced industrial projects. Generators continue to present a major procurement risk due to extended lead times and global demand pressures.
For life sciences developers, this means procurement strategies must begin earlier. Early engagement with suppliers, forward purchasing of critical equipment and diversified sourcing strategies can all help mitigate supply chain risk and improve programme certainty.
Labor shortages continue to represent as a significant risk. Life sciences projects require specialist expertise throughout design, construction, commissioning and validation. In addition to general construction trades, projects often depend on cleanroom specialists, process engineers, validation professionals and experienced commissioning teams. These skills are already in short supply across many markets.
The challenge extends beyond construction. 77% of healthcare and life science employers are struggling to find the skilled talent they needi. At the same time, construction markets across Australia, Singapore and Japan continue to contend with broader workforce shortages.
The consequences are significant. Labor scarcity can constrain contractor capacity, increase wage inflation and make it more difficult to resource specialist project phases. It can also create program delays when critical expertise is not available at the required stage of delivery.
In response to these challenges, many life sciences organizations are exploring modular construction and Design for Manufacture and Assembly (DfMA) as a way to improve project outcomes.
Modular approaches for life sciences facilities involves fabricating building components, cleanrooms, process skids, MEP racks, or entire room modules offsite in a controlled factory environment, then transporting and assembling them on site. This can reduce on-site labor requirements, provide greater cost certainty and programme predictability.
The approach is particularly relevant in today's market conditions. By shifting work into controlled manufacturing environments, modularisation can reduce exposure to labour shortages, improve productivity and minimise some of the risks associated with constrained site resources and utility limitations.
In Singapore for example, the Ministry of National Development is highly supportive of DfMA and off-site fabrication through its Construction Industry Transformation Map, which aims to improve productivity and modernise project delivery practices across the construction industry. Linesight continues to see growing interest in these approaches as life sciences clients seek greater resilience and certainty in delivery.
The long-term outlook for life sciences construction across Asia-Pacific remains favourable. Demand for pharmaceutical manufacturing, biotechnology research, advanced therapies and healthcare infrastructure continues to support significant capital investment across the region.
However, project success is increasingly determined not by demand alone, but by an organisation's ability to navigate execution risk. Power availability, labour constraints, long-lead equipment procurement, commodity volatility and supply chain resilience are emerging as the key factors influencing project outcomes.
For pharmaceutical and biotech investors, competitive advantage will increasingly come from securing certainty. Those who engage early, understand supply chain exposure and build resilient delivery strategies will be best positioned to convert strong market opportunity into successful project outcomes.
Stephanie will be attending the ISPE Singapore Conference & Exhibition 2026 from 19 August. If you are attending, complete the form below to arrange a conversation with Stephanie.
